Skip to content
Back to announcement

20240731_SILO_Laporan Informasi dan Fakta Material_31689474_lamp1.pdf

Other Text extracted SILO

Source file signed link, expires in 15 minutes

This browser can't display the PDF inline. Open it in a new tab.

Extracted text 3

Page 1
PRESS RELEASE
FOR IMMEDIATE RELEASE
31 July 2024

  Siloam Hospitals Sustained Growth supported by High Complexity
                         Clinical Programs

1H2024 vs 1H2023 Financial and Operational Highlights:
   • Revenue, Underlying EBITDA, and Underlying Net Profit booked at Rp4.66tn, Rp1.39tn, and
      Rp644bn, growing 14%, 15.3%, and 24.9% Year-on-Year respectively.
   • Inpatient Admissions, Inpatient Days, and Outpatient volume in 1H2024 recorded at 164,466
      patients, 515,433 days, and 2,069,094 visits, and each grew by 15%, 14.2%, and 12.7% Year-on-
      Year respectively.

PT Siloam International Hospitals Tbk (“Siloam” or the “Company”; stock code: “SILO”)

Tangerang, 31st July 2024 – Siloam announced its financial and operational results for first half of 2024.
The Company is continuing its sustained growth whereby YoY revenue growth reflects strong execution
of strategy, growth of clinical programs, and optimizing value in hospitals that were ramping up.

Through continuous improvement on the range and complexity of clinical programs, Siloam successfully
maintained its performance for the second semester of 2024, driven by higher Average Revenue Per
Occupied Beds (ARPOB) resulting from high complex clinical programs in Cardiology, Oncology,
Neurology, Gastroenterology, and Orthopaedic (CONGO). ARPOB in 2Q2024 improved by 3.5% YoY and
1.1% QoQ respectively.

Siloam has managed to maintain its favourable payer mix with 81.9% of total Revenue derived from
private patients, including Out of Pocket, Corporate and Insurance. The remaining 18.1% were derived
from BPJS payer group.

While optimizing existing capacity, the Company continues its expansion strategy of opening one to two
hospitals per year, as for example Siloam Hospitals Makassar Extension which will be completed by the
end of 2024 and Siloam Hospitals Lippo Village Oncology Centre in the first quarter of 2025. As of 1H2024,
Siloam Hospitals operated more than 4,000 beds, with 69% occupancy rate or an increase of 9.4%
compared to 1H23 on a blended basis.

Siloam recorded an increase in Inpatient and Outpatient volumes. As of 1H2024, Inpatient admissions
grew by 15% to 164,466 patients compared to 142,961 patients in 1H2023 and Outpatients visits grew by
12.7% to 2,069,094 visits compared to 1,835,666 visits in 1H2023. The Company has maintained its
Outpatient volume above 1 million visits every quarter.

The Company has successfully sustained its performance despite the seasonality impact of quarter 2. In
1H2024, Net Revenue, Normalized EBITDA and Normalized Net Profit were higher by 14%, 15.3%, and
24.9% respectively.
Page 2
       Operational Results                1H2024    1H2023            % growth 2Q2024               2Q2023       % growth
 Operational beds (Beds)                     4,120     3,956              4.1%     4,120               3,956         4.1%
 Inpatient Admissions                      164,465   142,961             15.0%    81,625              71,645        13.9%
 Inpatient Days (days)                     515,433   451,528             14.2%   255,175             226,204        12.8%
 Occupancy Rate (%)                          69.0%     63.1%              9.4%     68.0%               64.5%         5.4%
 Outpatients Visits                      2,069,094 1,835,666             12.7% 1,018,077             910,407        11.8%


   Financial Results (IDR mn)             1H2024    1H2023            % growth 2Q2024     2Q2023                 % growth
 Net Revenue                             4,659,285 4,086,314             14.0% 2,318,529 2,039,727                  13.7%
 Underlying EBITDA                       1,394,109 1,209,150             15.3%   687,850   606,774                  13.4%
 Underlying EBITDA Margin (%)                  29.9%         29.6%          1.1%         29.7%          29.7%         -0.3%
 Underlying Net Profit                      644,851       516,393         24.9%       311,126        259,023         20.1%
 Underlying Net Profit Margin (%)              13.8%         12.6%          9.4%         13.4%          12.7%          0.7%



Remarks from Siloam’s President Director:

Siloam’s President Director, Mr. Benny Haryanto, commented on the results: “Siloam continued to show
resiliency and maintained its financial and operational results in the first half of 2024. Management
continues to execute its strategic plan diligently to provide exceptional care to patients while achieving
operational excellence and financial sustainability.“
lain (radiasi, hormonal, sunti


For more information, please contact:

Investor Relations Support
Siloam Hospitals Group
Ir.support@siloamhospitals.com



About Siloam Hospitals Group

PT Siloam International Hospitals Tbk (“Siloam Hospitals”) is a network of private hospitals in Indonesia committed
to providing high quality health services in Indonesia. Starting business in 1996, Siloam Hospitals currently manages
and operates 41 hospitals, consisting of 15 hospitals in the Greater Jakarta area and 26 hospitals spread across the
islands of Java, Sumatra, Kalimantan, Sulawesi, Bali, Nusa Tenggara and Ambon. Siloam Hospitals Group also
operates 73 Siloam Clinics.

Siloam Hospitals' vision is to provide international quality healthcare and reach all levels of society on a national
scale based on Godly compassion which is the basis for Siloam Hospitals to respond to the dynamic social
transformation in Indonesia. Siloam Hospitals' mission is to be the trusted choice for world-class holistic healthcare,
health education and research.

Siloam Hospitals is the pioneer of Joint Commission International (JCI) accreditation for hospitals in Indonesia. JCI is
an international accreditation agency based in the United States that focuses on improving the quality of health
care and patient safety.

For more information about Siloam Hospitals, visit www.siloamhospitals.com.
Page 3
Disclaimer: This Press Release is prepared by Siloam Hospitals and is distributed only to convey general information. This Press Release is not
intended for a particular group or purpose and does not constitute a recommendation regarding the shares of Siloam Hospitals. No guarantee is
given regarding the completeness or certainty of the information contained. All opinions and estimates included in this Press Release are our
opinions as of this date and are subject to change without notice. Siloam Hospitals is not responsible for any losses that may occur to any party
due to part or all of the contents of this Press Release, Siloam Hospitals and affiliated companies including their employees and agents are not
responsible for any mistakes, omissions, omissions or inaccuracies that can happen.

Predictive Statements: Some of the statements in this Press Release are or may be predictive in nature. These statements generally contain
words such as "will", "hopes", "anticipates" or the like. By their nature, predictive statements carry risks and uncertainties that may cause realities
that are different from what is explained in this Press Release. Factors that can cause different realities include but are not limited to: the
economic, social and political situation in Indonesia; the health industry situation in Indonesia; market situation; additional regulatory burdens
in Indonesia, including regulations relating to the environment and regulatory compliance costs; fluctuations in foreign exchange rates; interest
rate development, capital costs and capital availability; anticipated demand and supply prices related to our health services and related capital
expenditures and other investments; construction costs; availability of health services; competition from companies and other locations; changes
in customer demand; changes in operational costs, including employee salaries, wages and training, changes in public and government policies;
our ability to stay competitive; financial conditions, business strategies and plans and targets set by our management for future work;
procurement of future income; compliance with environmental and remediation regulations. If, among other things, one or more of the risks or
uncertainties mentioned above occur, the actual results may differ materially than predicted, anticipated or projected. In particular, but not
limited, capital costs can increase, projects can be postponed and anticipated increases in production, capacity or implementation may not all
occur. Although we believe that our management's expectations expressed in predictive statements are reasonable based on the information
we have at the moment, we cannot provide guarantees that these expectations can become reality. You should not depend on these statements
immediately. However, these statements apply only to the date they were stated, and we are not responsible for making updates or revisions,
even if new information, new events or anything is available.

File

File Open PDF
Source IDX
Size0.24 MB
Published31 Jul 2024
Pages3
Characters8,919
Text sourceEmbedded text layer
OCR confidence—

Names mentioned 2 people and organisations named in the text · linked when the evidence is strong

unresolved person Benny Haryanto p.2

Extraction attempts how the parser did, and what it refused

Nothing structured was extracted from this document — the attempts below say why.

No extraction attempted yet.

↑↓ select ↵ open ⇧↵ see every result